Works by Kim, Tae-Min


Results: 211
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 14, p. 3317, doi. 10.1080/10428194.2022.2126281
    By:
    • Ferhanoglu, Burhan;
    • Kim, Tae Min;
    • Karduss, Amado;
    • Brittain, David;
    • Tumyan, Gayane;
    • Al-mansour, Mubarak;
    • Zerga, Marta;
    • Song, Yuqin;
    • Rivas-Vera, Silvia;
    • Kwong, Yok Lam;
    • Lim, Soon Thye;
    • Yeh, Su-Peng;
    • Abdillah, Arif;
    • Huang, Zhongwen;
    • Dalal, Mehul;
    • Wan, Hui;
    • Hertzberg, Mark
    Publication type:
    Article
    25

    Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.

    Published in:
    Leukemia & Lymphoma, 2020, v. 61, n. 12, p. 2931, doi. 10.1080/10428194.2020.1791846
    By:
    • Straus, David;
    • Collins, Graham;
    • Walewski, Jan;
    • Zinzani, Pier Luigi;
    • Grigg, Andrew;
    • Sureda, Anna;
    • Illes, Arpad;
    • Kim, Tae Min;
    • Alekseev, Sergey;
    • Specht, Lena;
    • Buccheri, Valeria;
    • Younes, Anas;
    • Connors, Joseph;
    • Forero-Torres, Andres;
    • Fenton, Keenan;
    • Gautam, Ashish;
    • Purevjal, Indra;
    • Liu, Rachael;
    • Gallamini, Andrea
    Publication type:
    Article
    26
    27
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.

    Published in:
    2016
    By:
    • Sehui Kim;
    • Soo Jeong Nam;
    • Dohee Kwon;
    • Hannah Kim;
    • Eunyoung Lee;
    • Tae Min Kim;
    • Dae Seog Heo;
    • Sung Hye Park;
    • Chul Woo Kim;
    • Yoon Kyung Jeon;
    • Kim, Sehui;
    • Nam, Soo Jeong;
    • Kwon, Dohee;
    • Kim, Hannah;
    • Lee, Eunyoung;
    • Kim, Tae Min;
    • Heo, Dae Seog;
    • Park, Sung Hye;
    • Kim, Chul Woo;
    • Jeon, Yoon Kyung
    Publication type:
    journal article
    40
    41

    Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study.

    Published in:
    American Journal of Hematology, 2018, v. 93, n. 5, p. 607, doi. 10.1002/ajh.25043
    By:
    • Gambacorti‐Passerini, Carlo;
    • Orlov, Sergey;
    • Zhang, Li;
    • Braiteh, Fadi;
    • Huang, Huiqiang;
    • Esaki, Taito;
    • Horibe, Keizo;
    • Ahn, Jin‐Seok;
    • Beck, Joseph T.;
    • Edenfield, William Jeffrey;
    • Shi, Yuankai;
    • Taylor, Matthew;
    • Tamura, Kenji;
    • Van Tine, Brian A.;
    • Wu, Shang‐Ju;
    • Paolini, Jolanda;
    • Selaru, Paulina;
    • Kim, Tae Min
    Publication type:
    Article
    42
    43
    44
    45

    Artificial intelligence‐powered spatial analysis of tumor‐infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single‐center, retrospective, longitudinal cohort study.

    Published in:
    Thoracic Cancer, 2023, v. 14, n. 30, p. 3001, doi. 10.1111/1759-7714.15089
    By:
    • Kim, Dong Hyun;
    • Lim, Yoojoo;
    • Kim, Sukjun;
    • Ock, Chan‐Young;
    • Youk, Jeonghwan;
    • Kim, Miso;
    • Kim, Tae Min;
    • Kim, Dong‐Wan;
    • Kim, Hak Jae;
    • Koh, Jiwon;
    • Jung, Kyeong Cheon;
    • Na, Kwon Joong;
    • Kang, Chang Hyun;
    • Keam, Bhumsuk
    Publication type:
    Article
    46
    47
    48
    49
    50